RxDoctor Payments Data

Joseph Dai, MD

Dermatology · Madison, ALNPI 1831355700

Payments from drug & device makers

$6,608in general payments, 2019–2025

Across 307 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Organogenesis Inc.$1K
  • AbbVie$836
  • Novartis$810
  • Sanofi$792
  • Galderma Laboratories, L.p.$489
  • E.r. Squibb & Sons, L.L.C.$437
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$6,49398%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,608 in reported general payments places this provider in the 60th percentile of 168 dermatology providers in Alabama.

See all dermatology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,146,989
Medicare patients
676
Services billed
6,042

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$230,915
Cosentyx (2 Syringes)Secukinumab12$111,699
Tacrolimus59$8,824
Clobetasol Propionate74$2,894
Ketoconazole97$1,893
Fluorouracil16$971
Doxycycline Hyclate47$943
Triamcinolone Acetonide78$928
Metronidazole19$841
Imiquimod14$659
Mupirocin72$632
Mycophenolate Mofetil14$585
Hydroxychloroquine Sulfate14$577
Nystatin24$353
ValacyclovirValacyclovir Hcl15$252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$810$111,69912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 168 dermatology providers in Alabama.

Other dermatology in Madison

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →